Anaveon: Anaveon announces presentation of new data on development compounds ANV700 and ANV600 at the Society for Immunotherapy of Cancer 2024 Annual Meeting

- First presentation of ANV700, a targeted IL-21 employing proximity activated potentiation of cytokine signaling -- New mechanistic data provide insights into the mode of action of ANV600, currently in clinical development -BASEL, Switzerland, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced that it will present posters on ANV700 and ANV600 at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held from Friday, November 8, 2024, to Sunday, November 10, 2024, in Houston, Texas."ANV700 is a novel powerful PD-1 targeted therapeutic which focuses IL-21 signaling on T cells in the tumor microenvironment with the potential to reverse exhaustion," said Christoph Huber, Chief Scientific Officer of Anaveon. "We will further develop this molecule ...Full story available on Benzinga.com